CLINICAL TRIALS PROFILE FOR NEVANAC
✉ Email this page to a colleague
All Clinical Trials for Nevanac
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00332774 ↗ | Nevanac 3-Month Safety Study With QID Dosing | Completed | Alcon Research | Phase 3 | 2006-02-01 | The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery. |
| NCT00333255 ↗ | Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery | Completed | Alcon Research | Phase 3 | 2005-09-01 | The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye. |
| NCT00347204 ↗ | Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK | Completed | Allergan | Phase 4 | 2006-01-01 | To determine the ability of two topical Nonsteroidal Anti-inflammatory drops (Acular LS & Nevanac) to help control pain following Photorefractive Keratectomy (PRK). |
| NCT00347204 ↗ | Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK | Completed | Center For Excellence In Eye Care | Phase 4 | 2006-01-01 | To determine the ability of two topical Nonsteroidal Anti-inflammatory drops (Acular LS & Nevanac) to help control pain following Photorefractive Keratectomy (PRK). |
| NCT00348582 ↗ | Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery | Completed | Innovative Medical | Phase 4 | 1969-12-31 | The purpose of this study is to compare the clinical outcomes, safety and efficacy in patients randomized to receive either ketorolac or nepafanac following cataract surgery. |
| NCT00377546 ↗ | Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1% | Completed | Innovative Medical | Phase 4 | 1969-12-31 | To compare the penetration of three different NSAIDs. |
| NCT00780780 ↗ | Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema | Completed | Federal University of São Paulo | Phase 3 | 2007-07-01 | Diabetics retinopathy remains the major threat to sight in the working age population in the developed world. Furthermore, it is increasing as a major cause of blindness in other parts of the world, especially developing countries. Diabetic macular edema (DME) is a manifestation of diabetic retinopathy that produces loss of central vision. The triamcinolone intravitreal injection (1-4mg) is indicated to treatment of diabetic macular edema and it is considered an important treatment since it improves the visual acuity of patients with resolution of edema. Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop (0.1% solution). Nepafenac is manufactured by Alcon as Nevanac. It is approved by FDA as well as ANVISA. Pre-clinical studies suggest this medication showed efficacy to treat ocular posterior segment inflammation. The purpose of this study is evaluate the efficacy of intravitreal triamcinolone associated with nepafenac eye drops as treatment of diabetic macular edema. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Nevanac
Condition Name
Clinical Trial Locations for Nevanac
Trials by Country
Clinical Trial Progress for Nevanac
Clinical Trial Phase
Clinical Trial Sponsors for Nevanac
Sponsor Name
